NovelStem Swings to $2.38M Net Income in 2025 10-K, Reports $0.05 EPS
summarizeSummary
NovelStem International Corp. reported a significant financial turnaround in its 2025 10-K filing, swinging to a net income of $2.38 million, or $0.05 per share, compared to a net loss of $3.23 million, or $(0.07) per share, in 2024. This positive shift was primarily driven by a gain on disposal and relief of indebtedness resulting from corporate transactions, including the sale of its NetCo interest and settlement of litigation funding. Despite the reported net income, the company disclosed no operating revenue in 2025 and a loss from operations of $0.239 million, indicating that the core business remains in a development stage without active operations. This filing provides critical insight into the company's financial health and recent strategic actions, which are highly material for an OTC company with a sub-$500k market capitalization. Investors will need to assess the sustainability of its financial position given the non-operating nature of the reported income.
At the time of this announcement, NSTM was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $468.8K. The 52-week trading range was $0.01 to $0.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.